Citicoline vs Alpha-GPC: What Differs in Form, Evidence and Safety Questions
Citicoline and alpha-GPC are both choline-related ingredients marketed for memory; here is what the sources document about how they differ, and where no head-to-head evidence exists.
Content last updated . This page has not been medically reviewed.
Citicoline and alpha-GPC are two different choline-containing compounds that are sold for memory and focus. Only a handful of studies have put them side by side, and those studies were done in people with dementia, not in healthy adults. No source we read shows that one is better for a healthy person, so this page describes documented differences and leaves the choice to you and your clinician.
What each one is
Citicoline is also called CDP-choline. One Cochrane review explains that the same substance, when used as a drug, can be called citicoline, and that it is a frequently prescribed drug for cognitive impairment in several European countries.[1] Alpha-GPC is the shorthand for L-alpha glycerylphosphorylcholine, also known as choline alphoscerate.[2] For the nutrient they both relate to, see choline.
Evidence labels used here
"Head-to-head" means the two were compared directly in the same analysis. "Separate evidence" means each was tested against placebo in different studies, which cannot be lined up fairly. "Proper evidence not found" means we searched and found nothing usable.
What the studies found
| Question | What the source found | Strength of evidence |
|---|---|---|
| Direct comparison in dementia | A 2025 review pooled three randomized trials (358 people) and reported a better score for alpha-GPC on one clinical rating scale, with no significant difference on memory or word-fluency tests.[3] | Head-to-head, but only three trials, in dementia only |
| Citicoline alone in cognitive impairment | A 2023 review of seven studies in mild cognitive impairment, Alzheimer's disease or post-stroke dementia found improvement, but rated the overall study quality as poor.[4] | Separate evidence, low quality |
| Citicoline in older adults (Cochrane) | The review found no evidence of benefit on attention, and evidence of benefit on memory and behavior; the drug was well tolerated.[1] | Separate evidence, older trials |
| Alpha-GPC and stroke | A Korean health-insurance cohort of about 12 million people aged 50 or older linked alpha-GPC prescriptions to higher stroke risk.[2] | Observational association, not proof of cause |
| Either one in healthy adults | Proper evidence not found. We searched PubMed for head-to-head trials in healthy adults and found none. | Not established |
The stroke signal, read carefully
In the Korean study, users had a higher rate of total stroke (adjusted hazard ratio 1.46) than non-users, and the risk rose with longer use.[2] Users were older on average (68.3 versus 61.6 years) before matching, and the authors adjusted for usual risk factors.[2] A cohort study cannot show cause. The abstract also carries a 2026 erratum notice, and we read the abstract only, not the correction. We did not find a similar stroke finding for citicoline in the sources we read, which is not the same as showing citicoline is free of it. The details are on the alpha-GPC evidence page.
Why results do not transfer
The comparison trials were in people with dementia. A result in dementia does not tell us what happens in a healthy student or an adult with ordinary forgetfulness, and the reverse is also true.[3] Our page on why brain supplement results do not transfer explains this in more detail.
Safety questions to bring to a clinician or pharmacist
- Medicines: supplements can interact with medicines, so ask a pharmacist and see medication interactions.[5]
- Stroke, heart or blood-vessel history: given the alpha-GPC finding above, raise it before use.[2]
- Pregnancy, breastfeeding and children: many dietary supplements have not been tested in pregnant women, nursing mothers or children.[6]
- Surgery: some supplements can raise bleeding risk or change the response to anesthesia, so tell the surgical team.[6]
- Kidney or liver conditions: we did not find choline-specific guidance for these conditions in the sources we read, so ask a clinician.
- Quality: products vary, and the FDA says it does not approve supplements before sale.[5] See quality testing.
No universal winner
The documented differences are mostly in the form of the compound, the type of study, and the safety signal in observational data. Neither compound has been shown to be better for healthy people. For the single-ingredient guide, see citicoline and alpha-GPC and the citicoline trials page.
Frequently asked questions
Is citicoline the same as alpha-GPC?
No. They are different choline-containing compounds. Citicoline is CDP-choline; alpha-GPC is also called choline alphoscerate.[1][2]
Has anyone compared them directly?
Yes, in a 2025 review of three trials in people with dementia. It favored alpha-GPC on one rating scale and found no significant difference on memory or word fluency.[3]
Is either one proven to help memory in healthy people?
Proper evidence not found. The comparison and the citicoline reviews we read involved people with cognitive impairment or dementia.[3][4]
Does alpha-GPC cause strokes?
A large Korean cohort found higher stroke rates among users, but an observational study cannot show cause. Anyone with stroke risk should ask a clinician.[2]
Can I use either one instead of a prescribed medicine?
This page does not suggest that. Changes to prescribed medicines are for the prescriber, and memory change should be checked by a clinician first.[5]
References
- Fioravanti M, Yanagi M. Cochrane Database Syst Rev 2005. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Read 2026-10-23.
- Lee G et al. JAMA Netw Open 2021 (erratum 2026). Association of L-alpha Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. Abstract read; the 2026 erratum was not read. Read 2026-10-23.
- Sagaro GG, Amenta F. Front Neurol 2025. Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis. Read 2026-10-23.
- Bonvicini M et al. Nutrients 2023. Is Citicoline Effective in Preventing and Slowing Down Dementia? A Systematic Review and a Meta-Analysis. Read 2026-10-23.
- U.S. Food and Drug Administration (FDA), FDA 101: Dietary Supplements. Read 2026-10-23.
- National Center for Complementary and Integrative Health (NCCIH, US), Using Dietary Supplements Wisely. Read 2026-10-23.